Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cancer Genetics Inc (CGIX)

Cancer Genetics Inc (CGIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates

Cancer Genetics, Inc. (the "Company") (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced financial and operating results for the quarter ended...

CGIX : 3.04 (+4.83%)
Insights on the Cervical Cancer Diagnostic Testing Market to 2027 - Featuring BioVantra, Cancer Genetics & Cepheid Among Others

, /PRNewswire/ -- The report has been added to offering.

CGIX : 3.04 (+4.83%)
CPHD : 52.95 (unch)
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced financial and operating results for the fourth quarter and full year...

CGIX : 3.04 (+4.83%)
Global Whole Genome and Exome Sequencing Market: Focus on Product, Workflow, Application, End User, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2029

, /PRNewswire/ --Read the full report: • Product – Kits, Instruments• Workflow – Sample Extraction/Purification, Library Preparation, Library Quantification, Analysis (Bioinformatics)• Application...

CGIX : 3.04 (+4.83%)
ERFSF : 615.0000 (-0.07%)
GE : 6.69 (+1.67%)
ILMN : 370.25 (-0.63%)
LH : 172.68 (-0.25%)
QGEN : 45.31 (+1.71%)
NeoGenomics Announces Three-Year Contract to be Cornerstone Oncology and Cancer Testing Laboratory for Large, National Group Purchasing Organization

FT. MYERS, FL / ACCESSWIRE / March 2, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that the company has been awarded a three-year...

CGIX : 3.04 (+4.83%)
NEO : 35.85 (-1.27%)
Cancer Genetics Issues Letter to Shareholders

Cancer Genetics, Inc. (Nasdaq: CGIX) ("Cancer Genetics" or the "Company"), a leader in drug discovery and preclinical oncology and immuno-oncology services, today published a letter to shareholders from...

CGIX : 3.04 (+4.83%)
Delcath Systems Elects Seasoned Finance and Capital Markets Executive Elizabeth Czerepak to its Board of Directors

Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that Elizabeth Czerepak, a financial executive and board...

ALT : 22.35 (+10.53%)
CGIX : 3.04 (+4.83%)
DCTH : 8.95 (+0.79%)
Breakthrough Study Makes Cancer Detection Possible With a Simple Blood Test; Introduces a New Systemic Hallmark of Cancer

A new study by scientists from India, USA, and UK has presented clinical evidence for an innovative test that can detect clusters of cancer cells in the blood of asymptomatic individuals as a non-invasive...

CGIX : 3.04 (+4.83%)
Breakthrough Study Makes Cancer Detection Possible With a Simple Blood Test; Introduces a New Systemic Hallmark of Cancer

- The new study by Datar Cancer Genetics [https://datarpgx.com/] has used a revolutionary new method that detects clusters of tumor cells circulating in the bloodstream and helps in early detection of...

CGIX : 3.04 (+4.83%)
Cancer Genetics Reports Third Quarter 2019 Financial Results and Provides Strategic Business Update

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the third quarter...

CGIX : 3.04 (+4.83%)
Cancer Genetics, Inc. Announces Strategic Transactions

Note Payment Received from Interpace Diagnostics Group, Inc.

CGIX : 3.04 (+4.83%)
IDXG : 5.17 (-0.77%)
Cancer Genetics Announces 1-for-30 Reverse Stock Split

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a 1-for-30 reverse stock split of its outstanding...

CGIX : 3.04 (+4.83%)
Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners

Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes...

CGIX : 3.04 (+4.83%)
IDXG : 5.17 (-0.77%)
Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ --

CGIX : 3.04 (+4.83%)
Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

https://mma.prnewswire.com/media/1008171/Datar_Cancer_Genetics_Limited_Logo.jpg

CGIX : 3.04 (+4.83%)
Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the second quarter...

CGIX : 3.04 (+4.83%)
Cancer Genetics, Inc. Announces Strategic Transactions

Sale of BioPharma business to Interpace Diagnostics Group, Inc.

CGIX : 3.04 (+4.83%)
IDXG : 5.17 (-0.77%)
Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business Supported by Investment from Ampersand Capital Partners

Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET

IDXG : 5.17 (-0.77%)
CGIX : 3.04 (+4.83%)
NHLD : 1.9306 (-2.00%)
Innovate Biopharmaceuticals Expands Its Management team with the Addition of Ed Sitar as Its Chief Financial Officer

Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced the appointment...

CGIX : 3.04 (+4.83%)
INNT : 0.5600 (-20.23%)
LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space

The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.

DGX : 116.82 (+0.84%)
LH : 172.68 (-0.25%)
CGIX : 3.04 (+4.83%)
ICLR : 169.96 (-2.48%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +0.29 , SEDG +2.26 , THC +0.97 , TER -1.08 , LITE -1.41
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar